

**IN THE UK COVID-19 PUBLIC INQUIRY
BEFORE BARONESS HEATHER HALLETT
IN THE MATTER OF:**

THE PUBLIC INQUIRY TO EXAMINE THE COVID-19 PANDEMIC IN THE UK

**SUBMISSIONS ON BEHALF OF COVID-19 BEREAVED FAMILIES FOR JUSTICE
CYMRU IN ADVANCE OF THE PRELIMINARY HEARING FOR MODULE 4
(ON THE KEY LINES OF ENQUIRY)**

Introduction

1. These submissions are made on behalf of Covid-19 Bereaved Families for Justice Cymru (CBFJ Cymru) in relation to the proposed key lines of enquiry for Every Story Matters in relation to Module 4. A separate document has been filed containing other submissions.

Further Proposed Key Lines of Enquiry

2. We are grateful for the work done by the Inquiry Legal Team so far in relation to this exercise. In addition to the KLOEs identified at paragraph 58 of the CTI's note, we propose that the following KLOEs be added:

(c) Practicalities of the vaccine roll-out, including

- i. The impact of geographical differences on access to the vaccine;
- ii. The experience of older people and of disabled people when accessing the vaccine including:
 - i. The impact of shielding on access to the vaccine, including access to public transport;
 - ii. Internet access/literacy;
 - iii. The quality of government/NHS communications; and
 - iv. Physical access to vaccine centres.

- iii. The inequalities and/or barriers faced by those living in rural communities (what is often referred to as “the postcode lottery”);
- iv. The impact of severe weather on access to the vaccine;
- v. The differences in approach between different Local Health Boards, care homes, NHS Trusts, and primary care facilities;
- vi. The perception and understanding of the rationale for prioritisation of NHS staff and healthcare workers who were not patient-facing; and
- vii. Prioritisation of frontline emergency services workers (including the definition of “frontline”) – some of those represented by CBFJ Cymru worked as frontline key workers during the pandemic.

(d) Provision of Antiviral medication, including

- i. Experiences and barriers to accessing antiviral medications; and
- ii. Perception of whether there was fair and equitable access to antiviral medications before the rollout of the vaccine.

(e) The impact on the development of other medicines

- i. Experiences of how the pharmaceutical and scientific attention paid to the Covid-19 vaccine impacted the development of medicines to treat conditions other than Covid-19; and
- ii. Experiences of delays in receiving medication to treat conditions other than Covid-19 as a result of the attention paid to treating Covid-19.

(f) Experiences in healthcare settings with unvaccinated healthcare workers

- i. The impact of vaccine mandates on healthcare workers; and
- ii. Experiences of receiving healthcare in settings with unvaccinated healthcare workers.

CRAIG COURT
Harding Evans Solicitors
RLR

BETHAN HARRIS
KIRSTEN HEAVEN
NIA GOWMAN
LAURA SHEPHERD

5th September 2023